Register Now

For five decades, India’s pharma industry ran the world’s most efficient generics engine, building scale, reliability and global trust.

That strength remains. But the industry is now entering a new phase, one driven by innovation, biologics and advanced drug delivery science.

Indian companies are moving into biosimilars, complex generics and specialty medicines. AI is beginning to reshape discovery and formulation development. At the same time, global pharma companies are expanding research partnerships and R&D centres in India.

Government policy is reinforcing this shift. Initiatives such as Biopharma SHAKTI, the PRIP Scheme and the BioE3 policy together represent more than ₹15,000 crore in targeted investment aimed at strengthening India’s pharma innovation ecosystem

For India’s pharma industry, this transition brings both opportunity and challenge.

So, FDD Conclave 2026, to be held on June 5, 2026, at Le Meridien, Hyderabad, will bring the formulation and drug delivery community together to exchange insights and identify practical pathways to strengthen India’s pharma ecosystem.

Under the theme, “India Pharma Inc’s Second Act” the discussions will focus on the technologies, scientific capabilities, partnerships and regulatory strategies required to translate innovation into real-world therapies.

For more information, visit the website: https://fdd.expresspharma.in/